AbbVie’s Ubrogepant Study: A Potential Game-Changer for Pediatric Migraine Treatment

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie is conducting a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of oral ubrogepant tablets for the acute treatment of migraine in children and adolescents aged 6-17. This study aims to address the significant burden of migraine in this age group by testing ubrogepant, a drug already approved for adults, in younger patients.

The study involves administering oral tablets of ubrogepant in varying doses to determine the most effective treatment for children and adolescents experiencing migraines. Participants are randomized to receive either a low or high dose of ubrogepant or a placebo, with an option for a second dose if needed.

This interventional study employs a randomized, parallel assignment model with triple masking to ensure unbiased results. The primary purpose is to assess treatment efficacy.

The study began on January 13, 2022, with an estimated primary completion date in 2025. The latest update was submitted on August 13, 2025, indicating ongoing recruitment and progress.

The outcome of this study could significantly impact AbbVie’s stock performance by expanding the market for ubrogepant to a younger demographic. This development may influence investor sentiment positively, especially if the results demonstrate safety and efficacy. Competitors in the migraine treatment space will be closely monitoring these developments.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.